US Edition
Published • loading... • Updated
Biotech Beactica and research institute LISCO secured €2.5M to advance glioblastoma therapy to the clinic - European Biotechnology Magazine
Summary by European-biotechnology.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Biotech Beactica and research institute LISCO secured €2.5M to advance glioblastoma therapy to the clinic - European Biotechnology Magazine
The European Innovation Council (EIC) has funded the collaborative GLIOBREAK project, bringing together Swedish biotech Beactica Therapeutics and the Belgian KU Leuven Institute for Single-Cell Omics (LISCO) to advance Beactica’s small-molecule candidate, BEA-17, as a precision immunotherapy for glioblastoma, the most common and aggressive form of brain cancer, which currently has limited treatment options. The post Biotech Beactica and research…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
